Prilosec Bioequivalence Study in Healthy Volunteers

Bioequivalence, AUC, Cmax, Pharmacokinetics Clinical Trial

Official title:
An Open-label, Randomized, Single-center, 4-way Crossover, Single Dose Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous Solvent Based Capsules Manufactured by AstraZeneca With Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck

Status Completed

Clinical Trial Summary

This is An Open-label, Randomized, Single-center, 4-way Crossover, Single dose Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous solvent Based Capsules Manufactured by AstraZeneca with Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Bioequivalence, AUC, Cmax, Pharmacokinetics

Clinical Trial Details

NCT number	NCT01921920
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 1
Start date	August 2013
Completion date	November 2013

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03121820` - Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects	Phase 1
	Completed	`NCT02185534` - Clopidogrel Bioequivalence Study in Healthy Subjects	Phase 1